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ABSTRACT
Upon sunitinib treatment of metastatic renal cell carcinoma patients eventually 
acquire resistance. Our aim was to investigate microRNAs behind sunitinib resistance.
We developed an in vivo xenograft and an in vitro model and compared 
morphological, immunhistochemical, transcriptomical and miRNome data changes 
during sunitinib response and resistance by performing next-generation mRNA and 
miRNA sequencing. Complex bioinformatics (pathway, BioFunction and network) 
analysis were performed. Results were validated by in vitro functional assays.
Our morphological, immunhistochemical, transcriptomical and miRNome data 
all pointed out that during sunitinib resistance tumor cells changed to migratory 
phenotype. We identified the downregulated miR-1 and miR-663a targeting FRAS1 
(Fraser Extracellular Matrix Complex Subunit 1) and MDGA1 (MAM Domain Containing 
Glycosylphosphatidylinositol Anchor 1) in resistant tumors. We proved firstly miR-
1-FRAS1 and miR-663a-MDGA1 interactions. We found that MDGA1 knockdown 
decreased renal cancer cell migration and proliferation similarly to restoration of 
levels of miR-1 and miR-663.
Our results support the central role of cell migration as an adaptive mechanism 
to secure tumor survival behind sunitinib resistance. MDGA1, FRAS1 or the targeting 
miRNAs can be potential adjuvant therapeutic targets, through inhibition of cancer 
cell migration, thus eliminating the development of resistance and metastasis.
INTRODUCTION
Renal cell carcinoma (RCC) is the most frequent 
malignancy of the adult kidney and its incidence has 
been steadily rising by 2–4% each year [1]. Up to 30% 
of patients present with metastases at diagnosis [2]. 
Patients with metastatic disease have 13 months median 
survival and a 5-year survival rate under 10% [3]. RCC 
is considered to be highly resistant to conventional 
therapeutic modalities including chemotherapy and 
radiation [4, 5]. It is highly vascularized cancer due 
to the hypoxia induced factor (HIF) stabilization as a 
consequence of VHL inactivation [6]. HIF accumulation 
leads to transactivation of molecules involved in 
angiogenesis including VEGF and PDGF [7]. The 
angiogenesis-inhibitor sunitinib is the first-line therapy 
for metastatic RCC. This small molecule multi-tyrosine 
kinase inhibitor [4] inhibits VEGFR-1, -2, -3, PDGFR-α 
and PDGFR-β, Fms-like tyrosine kinase 3 (FLT3), stem 
cell factor receptor (KIT), colony stimulating factor 
receptor type 1 receptor; and the glial cell line–derived 
neurotrophic factor receptor [8, 9]. Sunitinib treatment 
prolonged both progression-free and overall survival [10] 
and response rates to sunitinib were higher compared to 
interferon [11, 12]. 
Approximately 70% of patients show initial response 
to therapy but unfortunately in 6-12 months patients 
eventually acquire resistance and disease progression [13–
15]. Potential predictive markers for sunitinb treatment 
have been suggested, but none is in clinical practice [16]. 
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The remaining 30% are refractory to therapy (primary or 
intrinsic resistance) [15]. The causes behind resistance 
are not fully understood. A number of mechanisms have 
been proposed [17, 18]. Recent data suggest that resistance 
mechanisms include restoration of angiogenesis (through 
VEGF-independent pathways) and reduced bioavailability 
(increased efflux or lysosomal sequestration) [18]. 
Vasuclar co-option was also highlighted in other cancers 
[19]. Interestingly, current evidence also shows that TKI 
resistance is reversible [20, 21].
Recent literature suggested that miRNAs are 
involved in RCC pathogenesis (13), and the aqusition 
of aggressive behavior [22, 23], and their clinical utility 
as RCC biomarkers and therapeutic targets was also 
highlighted [24].
In the current study we developped an in vivo 
xenograft and in vitro models for sunitinib resistance. We 
performed next-generation RNA and miRNA sequencing 
of control, sunitinib-sensitive and resistant xenograft 
tumors. We aimed to find potential mechanisms and 
investigate the roles of miRNAs in sunitinib resistance.
RESULTS
Characterization of sunitinib sensitive and 
resistant xenograft RCC tumors
Mice were subcutaneously injected with human 
renal cell carcinoma cell lines. After tumor formation, 
animals received sunitinib treatment, as described in the 
materials section. RECIST criteria was used to assess 
reponse to treatment. Sunitinib treatment resulted in 
reduction/stability of tumor volume for about 4 weeks 
(Figure 1). Resistance started to develop after four 
weeks of treatment and tumors grew rapidly after 6-7 
weeks (Figure 1). On microscopic examintaion, tumors 
xenografts showed the classic RCC morphology (Figure 
2A).
As expected, when comparing tumors of the 
same size, there were significant differences in tumor 
characteristics detailed in Table 1, there were significantly 
larger necrotic areas in sunitinb-treated tumors compared 
to the untreated controls (Figure 2B-C). In sunitinib-
resistant tumors, necrotic areas were also seen (consistant 
with earlier treatment effect). Interestingly, resistant 
tumors exhibited focal sarcomatoid phenotype with 
spindle cells (Figure 2D) and also poorly differentiated 
cells (Figure 2E) compared to controls and sensitive 
tumors. 
When comparing sensitive to resistant tumors, 
sensitive tumors showed well-circumscribed border with 
fibrous capsule with inflammatrory infiltrate (Figure 2F–2G). 
Resistant tumors, on the other hand, had infiltrative 
irrelgular borders with invasion to surrounding adipose 
tissue. (Figure 2H). Moreover, sunitinb-resistant tumors 
had a much more aggressive behaviour, manifested by 
invasion to adjacent organs (Figure 2I) to In addition to 
the sarcomatoid differentiation and local invasion, resistant 
tumors showed more aggressive behaviour demonstrated 
by the presence of extensive vascular invasion (Figure 2J), 
and liver and lung metastases (Figure 2K). No metatsis were 
observed in sunitinb-sensitive tumors. 
Sunitinb-resistant tumors exhibited an interesting 
pattern of vascular co-option [19]. This was characterized 
by the migration of tumor cells along blood vessels of 
the alveolar walls of the lung without destruction of the 
alveolar spaces (Figure 2K–2L) [19]. This phenomenon 
was described before as a mechanism for tumor cells 
to escape antiangiogenic treatment effect by migrating 
through and maintaining normal architecture to be able 
to utilize the host’s normal vasculature (capillaries) for 
oxygen and nutrition. To our knowledge, this was not 
previously reported in kidney cancer.
Based on previous literature data regarding 
TKI resistance we investigated COX2 and PAX8 
immunostaining on resistance xenograft tumors [9, 25, 26]. 
We found slight COX2 expression increase is in resistant 
tumors (Figure 3A), which is in line with previous reports 
showing that COX2 inhibition was able to potentiate 
sunitinib effect in RCC xenografts [9]. There was also a 
significant reduction of E-cadherin expression in resistant 
compared to sunitinib-sensitive tumors, indicating the 
development of an EMT phenotype (Figure 3B). PAX8 
is a cell lineage restricted transcription factors essential 
for embryonic kidney development [26]. It is used in as 
a marker of renal differentiation. PAX8 expression was 
decreased in resistant tumors (Figure 3C), indicating the 
same trend towards dedifferentiation and the development 
of an epthelial to mesenchymal phenotype (EMT).
Differential gene and miRNA expression between 
sunitinib-sensitive and resistant xenograft RCC 
tumors
In order to obtain an insight about the biological 
attributes of sunitinib response and resistance, we 
compared the transcriptomic profiles (mRNA and 
miRNA) of control, sensitive and resistant tumors using 
next generation sequencing. Cluster analysis based on 
mRNA expression data showed that resistant tumors are 
separated from sunitinib-sensitive and control groups 
(Supplementary Figure 2A–2B). Similar results were 
obtained with miRNA clustering analysis (Supplementary 
Figure 2C–2D).
Interestingly, there were minimal significant 
molecular differences between sensitive tumors 
and controls (only 52 mRNAs and no miRNAs) 
(Supplementary Figure 2B, 2D). Comparing these 
two groups by BioFunction Analysis, we identified 
“proliferation of endothelial cells”, “vasculogenesis”, 
“growth of epithelial tissue” and “migration of cells” 
to be down-regulated in sunitinib-sensitive tumor 
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grafts (Supplementary Table 1). This is in keeping with 
the reported antiangiogentic role of typroisne kinase 
inhibitors. 
We next compared sunitinib-resistant to sensitive 
tumors, using Comparative Pathway Analysis for mRNA 
sequencing data and for tissue specific-target predicted 
miRNAs (TSTP miNRAs) to increase biological relevance 
of miRNA function. Genes related to cell migration, 
regulation of the Epithelial-Mesencymal Transition 
(EMT) Pathways, and human embryonic stem cell 
pluripotency were altered significantly in resistant tumors. 
Additionally, pathways related to immune response and 
inflammation was dysregulated between the two groups 
(Supplementary Table 2). These findings match with the 
differential inflammtoary response morphology that was 
observed [27]. BioFunction and Gene Ontology Analysis 
showed very comparable results (Supplementary Table 
2). Pathway analysis of miRNA expression differences in 
sunitinib-resistant to sensitive tumors showed strikingly 
similar result to pathway analysis of altered mRNA profile 
in the same samples including “Epithelial-Mesencymal 
Transition”, “Human Embryonic Stem Cell Pluripotency” 
Table 1: Semi-quantitative morphological  analysis of xenograft tumors
786O xenograft 
Untreated control
786O xenograft
Sunitinib sensitive
786O xenograft
Sunitinib resistant
Necrosis Area ++ ++++ +++
Sarcomatoid change/ poor differentiation _ _ +
Border Well/ regular Infiltrative/regular Infiltrative/irregular 
Invasion to adjacent _ _ +
Vascular invasion _ _ ++++
Distant Metastasis _ _ ++
Vascular co-option _ _ ++
Figure 1: Vehicle or sunitinib treatment in control (A) sensitive (B) and resistant (C–D) xenograft groups. Arrows show treatment start 
points. Mice were sacrified at the time points indicated by stars [*]. Sunitinib treatment resulted in stability of tumor volume for 3 weeks 
(no tumor regrowth) compared to control group. Resistance started to develop after four weeks of treatment and tumors grew rapidly after 
6-7 weeks.
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and signaling related to immune response. Molecular 
Functions related to growth factor receptors represented 
a considerable proportion of changed molecular functions 
regulated by miRNAs in sunitinib resistant tumors (Figure 
4A). Next, we compared the alterations in Diseases and 
BioFunctions analysis between mRNA and miRNA 
sequencing, and found strong resemblance between the 
relevance of the two levels of transcript regulation (Figure 
4B) indicating the role of miRNAs in sunitinib resistancy.
miRNAs are involved in sunitinib resistance in 
vitro
We developped an in vitro sunitinib resistance 
model to study the functional contribution of miRNAs to 
resistance. After optimization of sunitinib concentration 
(as detailed in the materials section), we used effective 
sunitinib concentration of 1 μM. Cells showed initial 
response and then developed resistance after 8 weeks 
of sunitinib treatment. After 16 weeks cells reached 
the original growth rate (Figure 5). We compared 
miRNA expression profile between cells treated for 48 
hours (sensitive) and for 23 weeks (resistant). miRNA 
alterations in vitro were cross-matched to our in vivo 
results (discussed above) and expectedly, comaparable 
results were obtained (Table 2). Performing Pathway 
and BioFunction analysis, we identified almost identical 
pathways and cellular processes through miRNA and 
gene expression analyses of the xenograft experiment 
(Supplementary Table 3).
Network analysis
In order to thoroughly investigate the role of 
the gene-miRNA axis of interaction in resistance, we 
integrated gene and miRNA expression data into an 
interaction network that is filtered to kidney-related 
miRNAs and mRNAs (Supplementary Figure 2E). Based 
on network structure and literature data, we identified 
miR-663a (downregulated in resistance) and MDGA1 
(overexpressed in resistance) as “hubs” (HUBs are 
defined as the top 10% of the nodes [genes or miRNAs] 
with highest number of interaction) that can play a central 
role in resistance (Supplementary Table 4). Additionally, 
MDGA1 has been also shown to increase cell motility [28]. 
miR-663a is predicted to target MDGA1 and is reported in 
Figure 2: Xenograft tumor tissue H&E staining. (A) Pretreatment tumors showed classic RCC morphology with rounded cells 
and occasional clearing of cytoplasm. (B) Large areas of necrosis were observed in sunitinib-sensitive tumor. (C) A bar graph comparing 
percentage areas of necorsis in sunitinib-treated vs. control xenografts. (D) Sarcomatoid phenotype with spindle cells was observed in 
resistant tumors. (E) Poorly differentiated cells were also seen in resistant tumors. (F) Low power magnification showing sensitive tumor 
with well-circumscribed border, fibrosis and chronic inflammatory infilitrate in the capsule. (G) Higher magnification showing pushing 
borders with fibrosis and inflammation in sunitinib-sensitive tumors. (H) Irregular infiltrative tumor margins with fat invasion were seen 
in sunitinib-resistant tumors (I) Resistant tumors were more aggressive with invasion to adjacent organs (skin dermis in this case). (J) 
Resistant tumors showed extensive vascular invasion (vessels indicated by arrows). (K) Lung metastasis in resistant tumors (arrow). 
Metatatsis showed vascular co-option pattern. (L) Vascular-co-option (arrow) in resistant tumor metastasis. Tumors travel along blood 
vessels of the wall of the alveoli while preserving the alveolar spaces.
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literature to induce cell differentiation and suppress tumor 
growth, invasiveness and cellular migration in multiple 
cancer types [29–31]. Our network also highlighted 
FRAS1 and miR-1. FRAS1 is predicted target of miR-1 
and is reported to be involved cell migration and invasion 
[32]. All four molecules are involved in cell motility and 
migration which is in line with our in vivo and in vitro 
results [33, 34], therefore we selected miR-1-FRAS1 and 
miR-663a-MDGA1 interaction for further investigation on 
RCC cell functions.
Validation of the effect of miR-1-FRAS1 
and miR-663a-MDGA1 interactions on cell 
behaviour
Our data showed inverse correlation in expression 
levels between miR-1 and FRAS1 and between miR-
663 vs MDGA1 (Figure 6A), indicating that the later 
genes are potential targets for the former miRNAs. 
We also found differential expression with maintained 
inverse correlation between these molecules in resistant 
compared to sunitinib-sensitive xenografts, indicating 
potential involvement in resistance (Figure 6A). We then 
experimentally validated these miRNA-gene interactions 
in cell line models. miR-1 and miR-663 mimics 
transfection resulted in reduction of the expression levels 
of FRAS1 and MDGA1, respectively at both the protein 
and mRNA levels (Figure 6B–6C). 
We then examined the effect of these molecules 
on cancer cell behavior. Loss-of-function experiments 
were done using MDGA1-specific siRNAs. MDGA1 
knockdown resulted in decreased migration and 
proliferation in ACHN, 786-O and Caki-2 kidney cancer 
cell lines (Figure 6D). Gain of fucntion experiments were 
done through restoring the downregulated miR-1 and miR-
663 by miRNA mimics transfection which also resulted 
in decreased cell migration (Figure 6E). However we 
could not detect any effect of miRNA mimics on viability/
proliferation (Figure 6E).
Taken together, our results show a multifactorial 
mechanism that results in resistance and support a central 
role of cell migration as an adaptive mechanism, which 
is mediated, at least in part, through a miRNA-target 
network of interaction. Resistant tumor cells acquire 
migratory phenotype and migrate to host vessels (vascular 
co-option) to overcome angiogenesis inhibition by TKIs.
Figure 3: Immunostaining patterns of sunitinib sensitive and resistant tumors. (A) COX-2 is increased in resistant tumors 
compared to control and sensitive ones. E-cadherin (B) and PAX8 (C) showed reduced staining in resistant tumors compared with control 
and sensitive tumors.
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DISCUSSION
Sunitinib resistance is a significant problem in 
treatment of metastatic RCC. We showed, through 
morphological, immunohistochemical and molecular 
analyses that changing to migratory phenotype play a 
role in resistance, and that resistant tumors acquire a 
more aggressive phenotype with metatstic potential. This 
represents a cornerstone for future research to identify 
adjuvant therapy to prevent or slow resistance. We found 
that PAX8 is decreased in resistant tumors. PAX8 is a 
cell lineage restricted transcription factor essential for 
embryonic kidney development [26]. It is expressed in 
renal tubular cells in fetal and adult kidneys and RCC [26]. 
PAX8 is also involved in the regulation of L1-CAM, an 
important therapeutic and prognostic protein in RCC [6]. It 
Table 2: Differentially expressed miRNAs between sunitinb-sensitive and resistant tumors* 
miRNA name in vitro (log2FC) in vivo (log2FC) adj.P.Val
hsa-miR-483-5p -8.5 -6.9 0.00000
hsa-miR-483-3p -3.2 -4.5 0.00000
hsa-miR-18a-3p -10.6 -2.3 0.00023
hsa-miR-618 -1.2 -1.7 0.03615
hsa-miR-486-3p -1.8 -1.6 0.01404
hsa-miR-1254 -1.1 -1.5 0.01257
hsa-miR-1247-5p -2.5 -1.4 0.01087
hsa-miR-875-5p -16.1 -1.4 0.03615
hsa-miR-939-5p -2.4 -1.4 0.03615
hsa-miR-7-1-3p -1.1 -1.4 0.00452
hsa-miR-454-5p -1.6 -1.2 0.00356
hsa-miR-1276 -8.9 -1.2 0.03128
hsa-miR-543 -3.7 -1.2 0.03615
hsa-miR-30e-3p -2.1 -1.2 0.00066
hsa-miR-30c-2-3p -2.8 -1.1 0.00042
hsa-miR-29c-5p 1.3 2.0 0.03128
hsa-miR-655-3p 9.8 2.2 0.00131
hsa-miR-145-5p 16.4 2.2 0.00011
hsa-miR-10b-5p 1.1 2.3 0.00001
hsa-miR-615-3p 1.6 2.7 0.00000
hsa-miR-9-5p 1.2 2.8 0.00218
hsa-miR-22-5p 1.5 3.0 0.00001
hsa-miR-15a-5p 4.7 3.2 0.00000
hsa-miR-758-3p 3.6 3.7 0.00001
hsa-miR-382-5p 5.3 4.0 0.00016
hsa-miR-183-3p 5.2 4.2 0.00002
hsa-miR-223-3p 8.7 4.2 0.00000
hsa-miR-335-3p 2.1 4.3 0.00000
hsa-miR-582-5p 8.4 4.5 0.00031
hsa-miR-154-5p 1.1 4.5 0.00000
hsa-miR-190a-5p 4.5 5.0 0.00000
hsa-miR-375 30.8 5.1 0.00000
hsa-miR-769-5p 12.1 7.0 0.00000
hsa-miR-889-3p 2.6 7.1 0.00000
hsa-miR-654-3p 5.8 7.5 0.00000
hsa-miR-92a-3p 12.4 9.2 0.00000
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was previoulsy shown that PAX8 downregulation resulted 
in increased L1-CAM expression and enhanced migration 
of kidney cancer cells [6]. Therefore PAX8 downregulation 
in sunitinib resistant cells could be a part of an evolving 
migratory phenotye. The role of PAX8 is, however, yet to 
be further investigated. Others reported increased PAX8 
expression in sarcomatoid RCC and metastases [35–37]. 
Besides, we found decreased E-cadherine in sunitinib-
resistant tumors, again confirming a migratory phenotype as 
loss of E-cadherin is considered to be a basic event in EMT.
It has been shown that drug resistance is reversible in 
RCC [20]. Our mRNA and miRNA transcription profiling 
showed no evidence of angiogenesis rebound (meaning that 
sunitinib still exerts its effect on growth factor receptors) 
in resistant tumors. Recent literature showed that TKI 
resistant cells exhibit vessel-cooption through increased 
migration [19]. Instead, pathways, biofunctions and GO 
categories of both mRNA and miRNA profiles pointed 
to cell migration. In both mRNA and miRNA sequencing 
analysis we found immune response and immune cell 
activation appeared. Interestingly angiogenesis is regulated 
especially in cell movement/migration aspect that was 
indicated by mRNA changes. The proliferative aspect 
of angiogenesis (proliferation if endothelial and smooth 
muscle cells) is likely controlled by miRNAs as it occurred 
in both miRNA and mRNA level. MiRNA expression 
changes are supported by our in vitro model which showed 
comparable changes.
Figure 4: (A) Molecular Function Analysis of miRNA changes in sunitinib resistant tumors. (B) Comparison of Diseases and BioFunction 
analysis of mRNA and miRNA sequencing between sunitinib resistant and sensitive xenograft tumors. BioFunction Terms are grouped by 
similar biological role (blue circles). Lines among similar BioFunction groups indicate connections in function. The clustered BioFunctions 
altered in mRNA expression profiling related to angiogenesis, immune response, cell movement were all significant in network with 
calcium signaling and cell proliferation. Other BioFunction terms related to vasculogenesis, cell migration and leukocyte activation were 
significant in both mRNA and miRNA sequencing results.
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Network analysis rely on individual molecular 
interactions, making them unbiased and advantageous 
over other system biology approaches like pathway, 
BioFunction or GO, for giving a better insight on the 
function of individual molecules. 
We identified two underexpressed miRNAs; 
miR-663 and miR-1, targeting MDGA1 and FRAS1, 
respectively. FRAS1 is involed in cell adhesion and 
it was previously reported that FRAS1 knockdown 
reduces A549 lung cancer cell migration and invasion 
through downregulation of focal adhesion signaling 
[32]. The role of MDGA1 protein was related to cell 
adhesion molecules implying MDGA1 involvement 
in cell migration and adhesion [28]. Its expression led 
to increased cell motility and cell-cell adhesion and 
reduced adhesion to extracellular matrix proteins in 
MDCK canine kidney cells [28]. Our data is the first 
to experimentally indicate miRNA regulation of either 
molecule. We firstly demonstrated that FRAS1 and 
MDGA1 were regulated by miR-1 and miR-663a, with 
subsequent potential role in sunitinib resistance through 
regulating cell migration.
miR-1 is a tumor suppressor miRNA that is 
downregulated in several cancers [33]. It targets a number 
of molecules including MET, Slug, CCND2, CXCR4 
[33]. It has been shown that miR-663 inhibits tumor 
cell migration and invasion of thyroid carcinoma and 
glioblastoma cells [30, 31]. Interestingly, beside tumor 
cells it inhibits migration of endothelial and vascular 
smooth muscle cells as well [38, 39]. This is of particular 
importance in RCC, which is a highly vascular tumor. 
The cause behind downregulation of miR-663 in resistant 
tumors still needs to be elucidated but studies suggeted 
increased promoter methylation in leukemic cells [40, 
41] which would correspond the findings that sunitinib 
resistance could be reversible [20] through methylation 
being a reversible epigenetic change.
Our findings are similar to a mechanism that 
was recently suggested for sorafenib resistance in 
hepatocellular carcinoma, namely, cell invasion mediated 
vessel co-option [19]. We found that resistant tumor 
cells acquire a migratory phenotype in the lack of blood 
supply, and through invading the host vessels they develop 
metastases. This is supported by other’s findigs that 
highly angiogenic primary ccRCC tumours can give rise 
to non-angiogenic metastases, which may be resistant to 
antiangiogenic therapy [40].
In conclusion, our phenotypic, immunhistochemical, 
mRNA and miRNA results support a central role of cell 
migration as an adapting mechanism. Tumor cells (instead 
of rebound angiogenesis) aquire a migratory phenotype 
and migrate to vessels (specifically to spots where there 
is more blood supply e.g. lung). Our hypothesis is that 
“changing to migratory phenotype” can be a mechanism 
of sunitinib resistance that can secure tumor cell survival. 
We identified the role of MDGA1 and FRAS1 regulated 
by miR-663a and miR-1 in this process. They can be 
potential adjuvant therapeutical targets. By inhibiting them 
it would be possible to inhibit migration hence slow or 
delay metastasis development. 
MATERIALS AND METHODS
Xenograft experiment 
Female NOD/SCID/γ mice were used for sunitinib 
resistance modelling. Animal procedures were done 
according to the institutional animal care guidelines. 
5-week-old mice were subcutaneously injected with 786-
O human RCC cell line (ATCC CRL-1932), 1.5 × 106 
Figure 5: In vitro sunitinib response and resistance in RCC cell lines. Different concentrations of sunitinib were tested and a 
concentration of 1 µM resulted in initial response followed by resistance after 8 weeks. Resistance index (RI) was calculated as previously 
described by Pénzváltó et al, 2013.
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cells in both flanks. Tumor size was measured twice per 
week using calipers, and tumor volume was calculated as 
width2 × lenght × 0.5. After tumor formation (~1 week), 
animals received oral gavage of sunitinib (purchased 
from Selleckchem, USA) as a citrate-buffered (pH 3.5) 
solution daily (7 days a week) at the dosage of 40 mg/kg 
or vehicle. Treatment response was assessed accourding 
to the RECIST criteria. Mice were sacrificed at the 
following timepoints: vehicle control (N = 4), sunitinib-
sensitive (3 weeks of treatment, with response and before 
signs of resistance) (N = 5), and the resistant group (10 
weeks of treatment, with resistance after initial resposne) 
(N = 7). Upon autopsy, xenograft tumors were stored in 
RNA later solution (Thermofisher Scientific, AM7021) 
until further use. Kidneys, livers and lungs were also 
collected for formalin fixation and immunhistochemical 
analysis.
In vitro sunitinib resistance model 
We investigated effect of different sunitinib 
concentrations on inducing apoptosis of RCC cell 
lines by Annexin V-Propidium Iodide flow cytometry 
(Supplementary Figure 1). At 0.1 μM sunitinib 
concentration that is considered to be pharmaclogically 
relevant we could not detect significant effect in line 
with other publications [20, 42]. Different concentrations 
were tested and and at sunitinib concentration of 1 μM, 
cells showed initial response and then cells developed 
resistance after 8 weeks of treatment.
Annexin V and propidium iodide flow cytometry
Annexin V-FITC (AV) and Propidium Idoide (PI) 
were purchased from BD (cat.#: 556420, 556463). All 
steps were performed according to the manufacturer’s 
instructions. After 24 h 0.1, 1.0, 5.0, 10.0 µM sunitinib 
treatment ACHN cells were harvested and suspended in 
binding buffer and count by Vi-Cell (Beckman). Annexin 
V assay was performed by staining with Annexin 
V-FITC for 15 min at 4°C in dark. Then stained cells 
were suspended in binding buffer and were analysed 
by flow cytometry after adding PI on a MACS Quant 
flow cytometer (Miltenyi Biotec, Auburn, CA, USA) at 
an event rate of < 500 evs/s. Data was dissected using 
Multicycle AV (FCS Express, DeNovo Software, Los 
Angeles, CA, USA). Intact cells are characterized by AV–/
PI–, early apoptosis by AV+/PI–, apoptosis by AV+/PI+ 
and necrotic/dead cells by AV–/PI– [43].
Viability/proliferation and migration assays
Cell proliferation/viability was controlled by WST-
1 cell proliferation reagent (Roche Applied Science) as 
previously described [44]. Cell migration was investigated 
by wound healing assay as described before [44, 45].
RNA extraction 
Total RNA extraction from cells and xenograft 
tissues for RT-qPCR and next generation sequencing 
was performed using miRNeasy kit (#217004, Qiagen, 
Mississauga, Canada), as in our previous publications 
[46]. RNA concentration and quality were asessed using 
NanoDrop (Thermo Scientific, Hudson, NH, USA).
Next generation sequencing
For miRNA sequencing, libraries were prepared 
using the Truseq Small RNA Library Sample prep kit 
(Illumina Inc., San Diego, CA, USA Cat #RS-200-0012). 
MiRNA was then precipitated, followed by adaptor 
ligation, cDNA synthesis, and amplification. and rapid 
run sequencing of 1 × 51 cycles (Illumina Inc., San 
Diego, CA, USA Cat #FC-402-4002), as described in the 
Supplemetary Methods. Reads were aligned to a database 
of mature RNA sequences (mirBase 20) using novoalign 
v2.08.02. The number of reads uniquely mapping to each 
mature RNA sequence were counted. Raw counts were 
normalized and transformed using the R package EdgeR 
and the voom transformation from the R package limma. 
Differential expression between groups was determined 
using the limma package.
For RNA sequencing, libraries were prepared using 
the TruSeq Stranded mRNA Sample Prep Kit (Illumina, 
Cat #RS-122-2101). Paired-end cluster generation 
(Illumina Inc., San Diego, CA, USA Cat #PE-401-3001) 
and sequencing of 2 × 101 cycles (Illumina Inc., San 
Diego, CA, USA Cat #FC-401-3001) was performed for 
all libraries on the Illumina Hi-Seq 2000/2500 platforms 
(Illumina Inc., San Diego, CA, USA), as detailed in our 
supplementary data. Paired end reads were trimmed to 
75bp. Reads were aligned to the UCSC hg19 reference 
genome using tophat (v2.0.3), followed by transcript 
assembly and estimation of expression levels (fpkm) 
with cufflinks (v2.0.2). Differential expression between 
groups was determined using the cuffdiff module of 
cufflinks, providing fold change estimates, associated 
p-values and q-values. The cufdiff output was reviewed 
Figure 6: (A) Expression of miR-1, FRAS1, miR-663a and MDGA1 in control, sunitinib sensitive and resistant xenografts. (B) 
Experimental validation of miR-1-FRAS1 interaction. miR-1 overexpression was able to significanly reduce the level of FRAS1 at both 
mRNA (measured by qRT-PCR, the two left graphs) and protein (assessed by western blot, the right graph) levels. (C) Experimental 
validation of the ability of miR-663a to target MDGA1. miR-663a over expression was able to significanly reduce the level of MDGA1 
mRNA (qRT-PCR analysis, left) and protein (western blot analysis, right). (D) siRNA resulted in decreased MDGA1 protein expression 
(western blot). MDGA1 knock-down resulted in significant reduction of the rate of cell proliferation and migration (wound healing assay). 
(E) Transfection of miR-1 and miR-663a mimics led to decreased cell migration but had no effect on proliferation.
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with the R package cummeRbund, to generate a variety 
of visualizations of the data and summaries of the most 
significant differently expressed events.
Bioinformatics analysis
Pathway analysis and tissue-specific target 
prediction. We used Ingenuity Pathway Analysis (IPA) for 
pathway and comparative analysis as previously described 
[44] to investigate the possible biological relevance of gene 
and miRNA expression changes in xenograft tissues and 
cell culture experiments (Ingenuity Systems, Redwood City, 
CA, USA). To identify expression alterations fold change 
filter was set to 2-fold, and then unpaired t-test was used 
to identify significant (p < 0.05) gene expression changes 
with multiple testing correction (Benjamini-Hochberg) 
in order to get better false discovery rate. miRNA targets 
were identified using TargetScan, miRecords, TarBase 
and Ingenuity Knowledge Base (IPAKB). We performed 
“tissue-specific target prediction” using a multistep 
filtration procedure as described before [44]. Briefly, using 
significantly deregulated miRNAs and mRNAs we selected 
miRNA-mRNA pairs by target predictions combined with 
the presence of inverse expression alterations.
Biofunction and Gene Ontology (GO) analysis 
Biofunctions were also determined by IPA gene set 
enrichment analysis and results were characterized by 
activation/inhibition Z-scores derived from gene/miRNA 
expression. GO categories of miRNA target genes were 
determined Ingenuity by using Generic Gene Ontology 
(GO) Term Mapper.
Network formation and structure analysis
In order to identify the role of genes and miRNAs 
in our sunitinib resistance model we generated a miNA-
target gene network. Ingenuity Knowledge Base (IPAKB) 
was used to discover interaction between genes and 
between genes and miRNAs based on known litearure 
data. We visualized and analyzed network structure using 
Cytoscape 3.1.0 software. We indicated mapping node’s 
colour and size by node degree as described previously 
[22].
miRNA expression profiling and qRT-PCR 
miRNA and gene expression 
We determined miRNA expression profile alteration 
in cell culture by TaqMan Array Human MicroRNA 
Card Set v3.0 (Thermofisher Scientific, Cat#: 4444913) 
containing assays for a total 754 of human microRNAs as 
described before [28]. Individual miRNA expression was 
determined on the Viia 7 Real-Time PCR System (Life 
Technologies) [27] using the individual TaqMan assays for 
miR-1 (Assay ID: 000385).
siRNA and miRNA mimics transfection
The primary 786-O and metastatic ACHN and Caki-
2 kidney cancer cell lines were purchased from American 
Type Culture Collection. Cells were transfected with 1 of 
2 different Locked Nucleic Acid® small interfering RNAs 
(siRNAs) as previously described [44] against MDGA1 
siRNA1 Cat 4392420# ID s49009) (100 nM) (Life 
Technologies), or siRNA2 Cat 4392420# ID s49011 (100 
nM) using Lipofectamine RNAiMAX (Life Technologies). 
Gene knockdown was verified on protein level by western 
blot using Santa Cruz Bio antibody (Cat# sc-168569 
MDGA antibody).
Primary 786-O and metastatic ACHN and Caki-
2 kidney cancer cell lines were transfected with 60 and 
120 nM any of miR-1 (ID: MC10617, miR-663a miRNA 
Mimics (ID: MC11581) (#:44640633, Life Technologies, 
Grand Island, NY, USA) using LipofectamineRNAiMAX 
(#13778075, Life Technologies) as we previously 
described [22].
Protein extraction, immunhistochemistry and 
western blotting 
FFPE xenograft tumor sections were stained 
with hematoxylin and eosin for assessing microscopic 
morphology, necrosis and invasive pattern. Percentage 
of tumor necrosis was calculated from whole-section 
scans. Additional sections were immunostained following 
standard procedure as we previously described [44]. 
Primary antibodies were used against COX2, PAX8 and 
E/cadherin (Abcam, Abcam, Invitrogen), the streptavidin-
biotin-peroxidase complex protocol using the LSAB+ 
Kit (DAKO, Carpenteria, CA, USA) was employed. 
Diaminobenzidine served as chromogen.
From fresh tissue samples total protein was 
extracted as we previously published [47]. Protein 
concentration was determined by BCA protein assay 
(Pierce Biotechnology, Rockford, IL, USA). Total protein 
was separated in 6% or 10% SDS– PAGE, transferred to 
a nitrocellulose membrane and incubated overnight with 
primary antibodies (MDGA1 antibody 1:200 dilution; 
FRAS1 (Cat# sc-98444, Santa Cruz Bio) antibody 1:100 
dilution). For loading control membranes were stripped 
and re-probed for mouse anti-β-actin (1:1000, Cell 
Signalling Technology Inc). Anti-mouse, anti-rabbit-
HRP conjugated IgGs were used as secondary antibodies 
(1:10000, W402B, W401B, Promega, Madison, WI, USA) 
or anti-goat –HRP from Santa Cruz Bio. Band intensities 
were quantified using Image J software (Bethesda, MD, 
USA).
Statistical analysis
 Differences were evaluated by Student’s T-test with 
Welch’s correction and by one-way ANOVA depending 
on group numbers. Bonferroni’s corrections were applied 
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for multiple comparison in pathway analysis. All data is 
presented as mean and standard error of the mean (SEM). 
P < 0.05 was considered significant.
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